Showing 3801-3810 of 5314 results for "".
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.
- Skinvisible Granted Patent for UVA Absorberhttps://practicaldermatology.com/news/20120320-skinvisible_granted_patent_for_uva_absorber/2459836/Skinvisible Pharmaceuticals, Inc. has been granted a new patent for its UVA sunscreen absorber. Skinvisible's new formulation with avobenzone provides eight hours of photostability, an advantage for those who spend many hours in the sun. The ingredi
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of
- Global Derm Market Reaches $11.6 Billionhttps://practicaldermatology.com/news/20120224-global_derm_market_reaches_116_billion/2459867/The global prescription dermatologic therapy market grew 6.2% from 2009 to 2001, to reach $11.6 billion. A new MarketWatch.com. report notes that the most dramatic gains were in the antiaging/photodamage, hair loss and hair removal, psoriasi
- New Rosacea Gel Coming Soonhttps://practicaldermatology.com/news/20120202-new_rosacea_gel_coming_soon/2459871/SkinCeuticals will soon unveil its Redness Neutralizer, a lightweight gel cream that prevents redness by targeting environmental triggers of inflammation leading to the onset of rosacea. Formulated wi
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://practicaldermatology.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- ILDS, WHO Launch Global Dermatology Training Hub to Address Care Gapshttps://practicaldermatology.com/news/ilds-who-launch-global-dermatology-training-hub-to-address-care-gaps/2486380/The International League of Dermatological Societies (ILDS), in collaboration with the World Health Organization (WHO), has launched the ILDS Dermatology Training Hub, a free online platform aimed at expanding access to dermatology education worldwide. The initiati
- Dermatology Residents Show Gains After Targeted Topical Formulation Educationhttps://practicaldermatology.com/news/dermatology-residents-show-gains-after-targeted-topical-formulation-education/2486095/A small survey-based study found that dermatology residents from 3 training programs reported limited formal education in topical vehicle formulation science, but showed improved comfort, confidence, and knowledge after a targeted educational intervention.
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- BE RADIANT: Bimekizumab Delivers Durable Plaque PsO Gains Through 3 Yearshttps://practicaldermatology.com/news/be-radiant-bimekizumab-delivers-durable-pro-gains-through-3-years/2485749/Bimekizumab treatment was associated with rapid and sustained improvements in patient-reported outcomes (PROs) among adults with moderate to seve